RNXT (RenovoRx) Revenue: $1.49 Mil (TTM As of Mar. 2026)


RNXT RenovoRx Inc RNXT
33 GF Score
Price $0.93
! 2 Warning Signs
View Full Analysis

What is RenovoRx Revenue?

RenovoRx RNXT -3.67% 33 Revenue is $1.49 Mil as of Mar. 2026. GuruFocus rates RNXT with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

RenovoRx's revenue for the three months ended in Mar. 2026 was $0.56 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $1.49 Mil. RenovoRx's Revenue per Share for the three months ended in Mar. 2026 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.04.

During the past 12 months, the average Revenue per Share Growth Rate of RenovoRx was 400.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


RenovoRx  (NAS:RNXT) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


RenovoRx Revenue Related Terms


RenovoRx Revenue Historical Data

* Premium members only.

The historical data trend for RenovoRx's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RenovoRx Revenue Chart

RenovoRx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.04 1.12

RenovoRx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.42 0.27 0.24 0.56

RNXT vs ACTU, ESLA, ELOX: Revenue Comparison

For the Biotechnology subindustry, RenovoRx's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RenovoRx Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RenovoRx's Revenue distribution charts can be found below:

* The bar in red indicates where RenovoRx's Revenue falls into.


RNXT
33GF Score
RenovoRx Inc RNXT
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RenovoRx Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $1.49 Mil mean?
RenovoRx (RNXT) has a Revenue of $1.49 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on RenovoRx and its competitors.
Is RenovoRx's Revenue too high?
RenovoRx's current Revenue is $1.49 Mil. Overall, RenovoRx has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does RenovoRx's Revenue compare to ACTU and ESLA?
RenovoRx's Revenue of $1.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on RenovoRx and its competitors. RenovoRx's current Revenue is $1.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RenovoRx stock overvalued right now?
RenovoRx (RNXT) has a current Revenue of $1.49 Mil. The current Revenue is $1.49 Mil. RenovoRx's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For RenovoRx (RNXT), the current Revenue is $1.49 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RenovoRx Business Description

Address 2570 West El Camino Real, Suite 320, Mountain View, CA, USA, 94040
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
33GF Score

Get the complete analysis for RNXT

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93
Price